Hamilton Insurance Group shares have risen about 50% over the past year but are still considered undervalued. The company posted a strong 25% return on equity in Q3, supported by robust underwriting, a quiet catastrophe season, and excellent investment returns, especially from its Two Sigma portfolio. Despite some margin compression and expected earnings normalization, Hamilton's balanced business model and high-quality liquid investments provide resilience. The stock trades at 6.5 times current earnings and 1.25 times book value, with a price target above $45 based on solid fundamentals and disciplined capital management.
Hamilton Insurance shares are the subject, with Pluang's market data providing context as of Nov 11, 2026 19:01 WIB. For readers following the Financials sector, 77 of 142 US stocks rose and 60 fell today. Notable movers include LMND at USD 41.50 with a 5.65% increase and a typical hold time of 28 days, CLSK at USD 6.92 up 5.33% with 87% sell order activity, and MARA at USD 7.72 rising 5.18% with 60% sell order activity.
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
